Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Patients with non-small cell lung cancer (NSCLC) are routinely treated with cytotoxic agents such as cisplatin. Through a genome-wide siRNA-based screen, we identified vitamin B6 metabolism as a central regulator of cisplatin responses in vitro and in vivo. By aggravating a bioenergetic catastrophe that involves the depletion of intracellular glutathione, vitamin B6 exacerbates cisplatin-mediated DNA damage, thus sensitizing a large panel of cancer cell lines to apoptosis. Moreover, vitamin B6 sensitizes cancer cells to apoptosis induction by distinct types of physical and chemical stress, including multiple chemotherapeutics. This effect requires pyridoxal kinase (PDXK), the enzyme that generates the bioactive form of vitamin B6. In line with a general role of vitamin B6 in stress responses, low PDXK expression levels were found to be associated with poor disease outcome in two independent cohorts of patients with NSCLC. These results indicate that PDXK expression levels constitute a biomarker for risk stratification among patients with NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TM4: a free, open-source system for microarray data management and analysis
Saeed, A. I., Sharov, V., White, J., Li, J., Liang, W., Bhagabati, N., Braisted, J., Klapa, M., Currier, T., Thiagarajan, M., et al. (2003) · BioTechniques · doi:10.2144/03342mt01 · Cited by 4,837
Mitochondrial membrane permeabilization in cell death
Kroemer, G., Galluzzi, L., & Brenner, C. (2007) · Physiological Reviews · doi:10.1152/physrev.00013.2006 · Cited by 3,598 · cited 2×
“266 Cell Reports 2, 257–269, August 30, 2012 a2012 The Authors identify 85 CRMs, encompassing known apoptosis regulators (negative: MCL1, BCL2L1, TFF1; positive: APAF1) (Bossenmeyer-Pourié et al., 2002; Kroemer et al., 2007), pro-survival proteins (IL6R), as well as multiple proteins involved in intermediate metabolis…”
BackgroundSelf-citationMetabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
Ward, P. S., & Thompson, C. B. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.014 · Cited by 3,233 · cited 1×
“Moreover, malignant cells can acquire resistance to otherwise lethal conditions in the context of (and sometimes due to) an extensive rewiring of metabolic circuitries (Kroemer and Pouyssegur, 2008; Ward and Thompson, 2012).”
BackgroundTumor cell metabolism: cancer's Achilles' heel
Kroemer, G., & Pouyssegur, J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.005 · Cited by 2,337
Self-citationGlobal Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317
Vousden, K. H., & Ryan, K. M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2715 · Cited by 959 · cited 1×
“Accumulating evidence indicates that the molecular cascades that regulate cell death and metabolism are extensively intertwined (Buchakjian and Kornbluth, 2010; Vousden and Ryan, 2009).”
BackgroundAwakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881 · cited 1×
“Cell death resistance can result from the inactivation/downregulation of positive modulators of apoptosis, like TP53 and ARF (Brown et al., 2009; Gil and Peters, 2006), or the hyperactivation/ overexpression of anti-apoptotic factors such as BCL-2-like and inhibitor of apoptosis proteins (Gyrd-Hansen and Meier, 2010;…”
BackgroundRegulation of the INK4b–ARF–INK4a tumour suppressor locus: all for one or one for all
Gil, J., & Peters, G. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1987 · Cited by 843 · cited 1×
“Cell death resistance can result from the inactivation/downregulation of positive modulators of apoptosis, like TP53 and ARF (Brown et al., 2009; Gil and Peters, 2006), or the hyperactivation/ overexpression of anti-apoptotic factors such as BCL-2-like and inhibitor of apoptosis proteins (Gyrd-Hansen and Meier, 2010;…”
BackgroundIAPs: from caspase inhibitors to modulators of NF-κB, inflammation and cancer
Gyrd-Hansen, M., & Meier, P. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2889 · Cited by 790
The inositol 1,4,5-trisphosphate receptor regulates autophagy through its interaction with Beclin 1
Vicencio, J. M., Ortiz, C., Criollo, A., Jones, A. W. E., Kepp, O., Galluzzi, L., Joza, N., Vitale, I., Morselli, E., Tailler, M., et al. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2009.34 · Cited by 289
Self-citationde La Motte Rouge, T., Galluzzi, L., Olaussen, K. A., Zermati, Y., Tasdemir, E., Robert, T., Ripoche, H., Lazar, V., Dessen, P., Harper, F., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0538 · Cited by 141
Self-citationInhibition of Chk1 Kills Tetraploid Tumor Cells through a p53-Dependent Pathway
Vitale, I., Galluzzi, L., Vivet, S., Nanty, L., Dessen, P., Senovilla, L., Olaussen, K. A., Lazar, V., Prudhomme, M., Golsteyn, R. M., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001337 · Cited by 77
Self-citation
Cited by
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042
Self-citationThe target landscape of clinical kinase drugs
Klaeger, S., Heinzlmeir, S., Wilhelm, M., Polzer, H., Vick, B., Koenig, P.-A., Reinecke, M., Ruprecht, B., Petzoldt, S., Meng, C., et al. (2017) · Science · doi:10.1126/science.aan4368 · Cited by 854
Alternative cleavage and polyadenylation: extent, regulation and function
Elkon, R., Ugalde, A. P., & Agami, R. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3482 · Cited by 804
Systems biology of cisplatin resistance: past, present and future
Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., Castedo, M., & Kroemer, G. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.428 · Cited by 782
“physical and chemical stress conditions, including the administration of CDDP.(272,282) In particular, we found that the cytotoxic response of a large panel of cancer cells to stress is”
BackgroundInfluentialSelf-citationAnticancer effects of the microbiome and its products
Zitvogel, L., Daillère, R., Roberti, M. P., Routy, B., & Kroemer, G. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.44 · Cited by 538
Self-citation
Metadata
- Authors
- Galluzzi, L., Vitale, I., Senovilla, L., Olaussen, K. A., Pinna, G., Eisenberg, T., Goubar, A., Martins, I., Michels, J., Kratassiouk, G., Carmona-Gutierrez, D., Scoazec, M., Vacchelli, E., Schlemmer, F., Kepp, O., Shen, S., Tailler, M., Niso-Santano, M., Morselli, E., Criollo, A., Adjemian, S., Jemaà, M., Chaba, K., Pailleret, C., Michaud, M., Pietrocola, F., Tajeddine, N., de La Motte Rouge, T., Araujo, N., Morozova, N., Robert, T., Ripoche, H., Commo, F., Besse, B., Validire, P., Fouret, P., Robin, A., Dorvault, N., Girard, P., Gouy, S., Pautier, P., Jägemann, N., Nickel, A.-C., Marsili, S., Paccard, C., Servant, N., Hupé, P., Behrens, C., Behnam-Motlagh, P., Kohno, K., Cremer, I., Damotte, D., Alifano, M., Midttun, Ø., Ueland, P. M., Lazar, V., Dessen, P., Zischka, H., Chatelut, E., Castedo, M., Madeo, F., Barillot, E., Thomale, J., Wistuba, I. I., Sautès-Fridman, C., Zitvogel, L., Soria, J.-C., Harel-Bellan, A., & Kroemer, G.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2012-08
- Volume
- 2
- Issue
- 2
- Pages
- 257-269
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W2105200826
- Cited by
- 131
- References
- 12
- FWCI
- 11.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.